TY  - CHAP
M1  - Book, Section
TI  - Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines
A1  - Hilal-Dandan, Randa
A1  - Brunton, Laurence L.
PY  - 2016
T2  - Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e
AB  - Many  new  agents  are  available  to  block  the  fundamental  mutations  that  cause  specific  cancers:  aberrant  growth  factor  receptors,  dysregulated  intracellular  signaling  pathways,  defective  DNA  repair  and  apoptosis,  and  tumor  angiogenesis.  The  primary  tools  for  inhibiting  these  targets  are  monoclonal  antibodies  that  attack  cell  surface  receptors  and  antigens,  and  synthetic  small  molecules  that  enter  cells  and  engage  critical  enzymes.  These  2  classes  of  drugs  have  very  different  pharmacological  properties.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1127554988
ER  -